JP2016531121A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016531121A5 JP2016531121A5 JP2016533392A JP2016533392A JP2016531121A5 JP 2016531121 A5 JP2016531121 A5 JP 2016531121A5 JP 2016533392 A JP2016533392 A JP 2016533392A JP 2016533392 A JP2016533392 A JP 2016533392A JP 2016531121 A5 JP2016531121 A5 JP 2016531121A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- groups
- alkyl
- optionally
- nitrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 24
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 125000003118 aryl group Chemical group 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 229910005965 SO 2 Inorganic materials 0.000 claims 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 235000010290 biphenyl Nutrition 0.000 claims 2
- 239000004305 biphenyl Substances 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000004688 alkyl sulfonyl alkyl group Chemical group 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 125000001769 aryl amino group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000005241 heteroarylamino group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361862759P | 2013-08-06 | 2013-08-06 | |
| US61/862,759 | 2013-08-06 | ||
| US201461954276P | 2014-03-17 | 2014-03-17 | |
| US61/954,276 | 2014-03-17 | ||
| PCT/US2014/049906 WO2015021128A1 (en) | 2013-08-06 | 2014-08-06 | Kdm1a inhibitors for the treatment of disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016531121A JP2016531121A (ja) | 2016-10-06 |
| JP2016531121A5 true JP2016531121A5 (enExample) | 2017-09-14 |
| JP6521967B2 JP6521967B2 (ja) | 2019-05-29 |
Family
ID=52461899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016533392A Active JP6521967B2 (ja) | 2013-08-06 | 2014-08-06 | 疾患の治療のためのｋｄｍ１ａ阻害剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US9790195B2 (enExample) |
| EP (1) | EP3030323B1 (enExample) |
| JP (1) | JP6521967B2 (enExample) |
| KR (1) | KR102255778B1 (enExample) |
| CN (1) | CN105592888A (enExample) |
| AU (1) | AU2014306149B2 (enExample) |
| BR (1) | BR112016002496B1 (enExample) |
| CA (1) | CA2920257C (enExample) |
| DK (1) | DK3030323T3 (enExample) |
| ES (1) | ES2734209T3 (enExample) |
| IL (1) | IL243976B (enExample) |
| MX (1) | MX383590B (enExample) |
| WO (1) | WO2015021128A1 (enExample) |
| ZA (1) | ZA201600901B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014084298A1 (ja) * | 2012-11-28 | 2014-06-05 | 京都府公立大学法人 | リシン構造を有するｌｓｄ1選択的阻害薬 |
| JP6521967B2 (ja) | 2013-08-06 | 2019-05-29 | イマーゴ バイオサイエンシーズ インコーポレイテッド | 疾患の治療のためのｋｄｍ１ａ阻害剤 |
| US11369577B2 (en) | 2014-11-26 | 2022-06-28 | IEO—Istituto Europeo di Oncologia S.r.l. | Reprogramming-based models of neurodevelopmental disorders and uses thereof |
| JP6727216B2 (ja) | 2015-02-12 | 2020-07-22 | イマーゴ バイオサイエンシーズ インコーポレイテッド | 疾患の治療のためのｋｄｍ１ａ阻害剤 |
| KR20180011331A (ko) | 2015-06-12 | 2018-01-31 | 오리존 지노믹스 에스.에이. | Lsd1 억제제와 관련된 바이오마커 및 그의 용도 |
| WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| DK3334709T3 (da) | 2015-08-12 | 2025-02-03 | Incyte Holdings Corp | Salte af en lsd1-hæmmer |
| FI3381896T3 (fi) | 2015-11-27 | 2023-04-21 | Taiho Pharmaceutical Co Ltd | Bifenyyliyhdiste tai sen suola |
| WO2017151732A1 (en) * | 2016-03-02 | 2017-09-08 | Beth Israel Deaconess Medical Center Technology Venture Office, Br2 | Therapeutic targets for lin-28-expressing cancers |
| CN120661674A (zh) | 2016-03-15 | 2025-09-19 | 奥莱松基因组股份有限公司 | 用于治疗实体瘤的lsd1抑制剂的组合 |
| JP2019512546A (ja) | 2016-03-16 | 2019-05-16 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｋｄｍ１ａ標的会合を決定するための方法、およびそれに有用な化学プローブ |
| RU2761829C2 (ru) * | 2016-06-07 | 2021-12-13 | Зе Дж. Дэвид Глэдстоун Инститьютс | Образуемые среднецепочечными жирными кислотами сложные эфиры бета-гидроксибутирата и бутандиола и композиции и способы на их основе |
| CN111194306B (zh) * | 2016-08-16 | 2023-05-16 | 伊美格生物科学公司 | 用于制备kdm1a抑制剂的方法和过程 |
| US20190256929A1 (en) | 2016-11-03 | 2019-08-22 | Oryzon Genomics, S.A. | Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents |
| US20190256930A1 (en) | 2016-11-03 | 2019-08-22 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
| RU2765152C2 (ru) | 2017-05-26 | 2022-01-26 | Тайхо Фармасьютикал Ко., Лтд. | Новое соединение бифенила или его соль |
| WO2018216795A1 (ja) | 2017-05-26 | 2018-11-29 | 大鵬薬品工業株式会社 | 新規なビフェニル化合物を用いた抗腫瘍効果増強剤 |
| AU2018276611B2 (en) | 2017-05-31 | 2022-01-06 | Taiho Pharmaceutical Co., Ltd. | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 |
| BR112020001285A2 (pt) | 2017-07-21 | 2020-07-28 | Buck Institute For Research On Aging | s-enantiômeros de beta-hidroxibutirato e butanodiol e métodos para sua utilização |
| AU2018309372B2 (en) | 2017-08-03 | 2024-08-15 | Oryzon Genomics, S.A. | Methods of treating behavior alterations |
| CN107828747B (zh) * | 2017-10-23 | 2020-11-03 | 中山大学附属第六医院 | 一种多肽及其编码基因和用途 |
| US12037317B2 (en) | 2018-01-25 | 2024-07-16 | Buck Institute For Research On Aging | Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds |
| JP7450559B2 (ja) | 2018-05-11 | 2024-03-15 | イマーゴ バイオサイエンシーズ インコーポレイテッド | 疾患の処置のためのｋｄｍ１ａ阻害剤 |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| WO2020152280A1 (en) * | 2019-01-24 | 2020-07-30 | Fundación Pública Andaluza Progreso Y Salud | Lsd1 inhibitors for use in the treatment of type 2 diabetes |
| HRP20251471T1 (hr) | 2019-03-20 | 2026-01-02 | Oryzon Genomics, S.A. | Postupci liječenja poremećaja hiperaktivnosti s deficitom pažnje korištenjem inhibitora kdm1a kao što je spoj vafidemstat |
| SI3941466T1 (sl) | 2019-03-20 | 2026-04-30 | Oryzon Genomics, S.A. | Vafidemstat za zdravljenje neagresivnih simptomov mejne osebnostne motnje |
| CN114341366A (zh) | 2019-07-05 | 2022-04-12 | 奥莱松基因组股份有限公司 | 用于使用kdm1a抑制剂个体化治疗小细胞肺癌的生物标志物和方法 |
| MX2022005811A (es) | 2019-11-13 | 2022-06-08 | Taiho Pharmaceutical Co Ltd | Sal novedosa de compuesto de terfenilo. |
| MX2022007113A (es) * | 2019-12-09 | 2022-07-11 | Imago Biosciences Inc | Inhibidores de la desmetilasa de la histona especifica de la lisina para el tratamiento de las neoplasias mieloproliferativas. |
| CA3231846A1 (en) | 2021-04-08 | 2022-10-13 | Tamara Maes | Combinations of lsd1 inhibitors for treating myeloid cancers |
| US20250032454A1 (en) * | 2021-10-18 | 2025-01-30 | Imago Biosciences, Inc. | Kdm1a inhibitors for the treatment of disease |
| US20250275969A1 (en) | 2022-05-09 | 2025-09-04 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| US20250295660A1 (en) | 2022-05-09 | 2025-09-25 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
| US20260151399A1 (en) | 2022-11-24 | 2026-06-04 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer |
| CN121850944B (zh) * | 2026-03-17 | 2026-06-09 | 苏州大学 | 一种笑气介导制备五元偶氮类化合物的方法 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005289517A1 (en) | 2004-09-24 | 2006-04-06 | Centre National De La Recherche Scientifique | Methods and compositions for treating flaviviruses, pestiviruses and hepacivirus |
| CA2676173A1 (en) | 2007-02-16 | 2008-08-28 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
| UA98961C2 (uk) | 2007-06-27 | 2012-07-10 | Астразенека Аб | Похідні піразинону та їх застосування у лікуванні легеневих захворювань |
| KR101586503B1 (ko) | 2007-09-13 | 2016-01-18 | 코덱시스, 인코포레이티드 | 아세토페논의 환원을 위한 케토리덕타제 폴리펩티드 |
| HUE027683T2 (en) | 2007-10-01 | 2016-10-28 | Codexis Inc | Ketoreductase polypeptides for the production of azetidinone |
| WO2010025287A2 (en) | 2008-08-27 | 2010-03-04 | Codexis, Inc. | Ketoreductase polypeptides for the production of 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine |
| EP2177502A1 (en) | 2008-10-17 | 2010-04-21 | Oryzon Genomics, S.A. | Compounds and their use |
| WO2010043721A1 (en) | 2008-10-17 | 2010-04-22 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
| JPWO2010143582A1 (ja) | 2009-06-11 | 2012-11-22 | 公立大学法人名古屋市立大学 | フェニルシクロプロピルアミン誘導体及びｌｓｄ１阻害剤 |
| WO2011035941A1 (en) | 2009-09-25 | 2011-03-31 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
| US8946296B2 (en) | 2009-10-09 | 2015-02-03 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use |
| RS55348B1 (sr) | 2010-04-19 | 2017-03-31 | Oryzon Gnomics S A | Inhibitori lizin specifične demetilaze-1 i njihova upotreba |
| US8765820B2 (en) | 2010-04-20 | 2014-07-01 | Universita Degli Studi Di Roma “La Sapienza” | Tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and/or LSD2 |
| DK2598482T3 (en) | 2010-07-29 | 2018-06-14 | Oryzon Genomics Sa | ARYLCYCLOPROPYLAMINE-BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE |
| EP2598480B1 (en) | 2010-07-29 | 2019-04-24 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| WO2012034116A2 (en) | 2010-09-10 | 2012-03-15 | The Johns Hopkins University | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders |
| US20120108500A1 (en) * | 2010-10-07 | 2012-05-03 | Naoki Sakane | Compositions and Methods for Modulating Immunodeficiency Virus Transcription |
| WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| WO2012071469A2 (en) | 2010-11-23 | 2012-05-31 | Nevada Cancer Institute | Histone demethylase inhibitors and uses thereof for treatment o f cancer |
| US20140163041A1 (en) | 2011-02-08 | 2014-06-12 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders |
| EP2712315B1 (en) | 2011-02-08 | 2021-11-24 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
| MX347913B (es) * | 2011-03-25 | 2017-05-17 | Glaxosmithkline Intellectual Property (No 2) Ltd | Ciclopropilaminas como inhibidores de desmetilasa 1 especifica de lisina. |
| BR112014002939A2 (pt) | 2011-08-09 | 2017-03-01 | Takeda Pharmaceuticals Co | composto, medicamento, método para profilaxia ou tratamento de doença, a doença sendo esquizofrenia, alzheimer, parkinson ou huntington, uso do composto, e, método para inibir o lsd1 |
| AU2012324803B9 (en) | 2011-10-20 | 2017-08-24 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors |
| US9469597B2 (en) | 2011-10-20 | 2016-10-18 | Oryzon Genomics S.A. | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors |
| WO2014084298A1 (ja) * | 2012-11-28 | 2014-06-05 | 京都府公立大学法人 | リシン構造を有するｌｓｄ1選択的阻害薬 |
| EP2740474A1 (en) | 2012-12-05 | 2014-06-11 | Instituto Europeo di Oncologia S.r.l. | Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a |
| WO2014164867A1 (en) * | 2013-03-11 | 2014-10-09 | Imago Biosciences | Kdm1a inhibitors for the treatment of disease |
| SG11201510369WA (en) * | 2013-06-25 | 2016-01-28 | Univ Canberra | Methods and compositions for modulating cancer stem cells |
| JP6521967B2 (ja) | 2013-08-06 | 2019-05-29 | イマーゴ バイオサイエンシーズ インコーポレイテッド | 疾患の治療のためのｋｄｍ１ａ阻害剤 |
| LT3105218T (lt) | 2014-02-13 | 2019-12-10 | Incyte Corp | Ciklopropilaminai kaip lsd1 inhibitoriai |
| CN121203988A (zh) | 2014-04-22 | 2025-12-26 | C-乐克塔股份有限公司 | 酮还原酶 |
| PL3160956T3 (pl) | 2014-06-27 | 2020-11-30 | Celgene Quanticel Research, Inc. | Inhibitory demetylazy-1 specyficznej dla lizyny |
| JP6727216B2 (ja) | 2015-02-12 | 2020-07-22 | イマーゴ バイオサイエンシーズ インコーポレイテッド | 疾患の治療のためのｋｄｍ１ａ阻害剤 |
| US20190070172A1 (en) | 2015-11-05 | 2019-03-07 | Imago Biosciences, Inc. | Lysine-specific histone demethylase as a novel therapeutic target in myeloproliferative neoplasms |
| KR102720551B1 (ko) | 2015-12-29 | 2024-10-21 | 미라티 테라퓨틱스, 인크. | Lsd1 억제제 |
| AU2017263361B2 (en) | 2016-05-09 | 2021-08-05 | Jubilant Epicore LLC | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors |
| CN110268067A (zh) | 2016-08-16 | 2019-09-20 | 伊美格生物科学公司 | 用于产生立体异构纯的氨基环丙烷的组合物和方法 |
| CN111194306B (zh) | 2016-08-16 | 2023-05-16 | 伊美格生物科学公司 | 用于制备kdm1a抑制剂的方法和过程 |
| WO2018106984A1 (en) | 2016-12-09 | 2018-06-14 | Constellation Pharmaceuticals, Inc. | Markers for personalized cancer treatment with lsd1 inhibitors |
| JP7450559B2 (ja) | 2018-05-11 | 2024-03-15 | イマーゴ バイオサイエンシーズ インコーポレイテッド | 疾患の処置のためのｋｄｍ１ａ阻害剤 |
-
2014
- 2014-08-06 JP JP2016533392A patent/JP6521967B2/ja active Active
- 2014-08-06 DK DK14834451.8T patent/DK3030323T3/da active
- 2014-08-06 AU AU2014306149A patent/AU2014306149B2/en active Active
- 2014-08-06 WO PCT/US2014/049906 patent/WO2015021128A1/en not_active Ceased
- 2014-08-06 MX MX2016001587A patent/MX383590B/es unknown
- 2014-08-06 CN CN201480053762.6A patent/CN105592888A/zh active Pending
- 2014-08-06 BR BR112016002496-6A patent/BR112016002496B1/pt active IP Right Grant
- 2014-08-06 US US14/910,423 patent/US9790195B2/en active Active
- 2014-08-06 ES ES14834451T patent/ES2734209T3/es active Active
- 2014-08-06 CA CA2920257A patent/CA2920257C/en active Active
- 2014-08-06 EP EP14834451.8A patent/EP3030323B1/en active Active
- 2014-08-06 KR KR1020167005974A patent/KR102255778B1/ko active Active
-
2016
- 2016-01-27 ZA ZA2016/00901A patent/ZA201600901B/en unknown
- 2016-02-04 IL IL243976A patent/IL243976B/en active IP Right Grant
-
2017
- 2017-08-02 US US15/667,166 patent/US10370346B2/en active Active
-
2019
- 2019-06-19 US US16/445,768 patent/US10882835B2/en active Active
-
2020
- 2020-12-01 US US17/108,663 patent/US11655226B2/en active Active